Navigator Medicines Advances NAV-240 into Phase 2a and NAV-242 into the Clinic, Supported by New Positive Data Presented at American Academy of Dermatology (AAD) Annual Meeting 2026SAN MATEO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Navigator Medicines Inc., a clinical-stage biotech company pioneering best-in-class bispecific antibodies (bsAb) for inflammatory disorders and autoimmune diseases in areas of high unmet need, today announced it has initiated patient dosing in its Phase 2a MAINSAIL clinical trial evaluating NAV-240, for the treatment of HS. The company has also entered Phase 1 clinical development for its next generation HLE bsAb, NAV-242. This important progress follows positive results across the program presented at the American Academy of Dermatology Congress 2026 in Denver, Colorado, U.S.A.
Navigator Medicines Accelerates Anti OX-40L and TNFα Bispecific Antibody Clinical Development Pipeline into Phase 2a and First-in-Human TrialsSCOTCH PLAINS, N.J., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Navigator Medicines Inc., a clinical-stage biotech company pioneering best-in-class bispecific antibodies (bsAb) for inflammatory disorders and autoimmune diseases in areas of high unmet need, today announced significant progress across its innovative anti-OX40L and anti-TNF combination pipeline, marking the Company's transition to a clinical focused organization with two investigational medicines in active clinical development.
Navigator Medicines Completes Last Participant Last Visit (LPLV) in Phase 1b Trial of NAV-240, an OX40L and Anti-TNFα Bispecific Antibody for Autoimmune DiseasesSCOTCH PLAINS, NJ., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Navigator Medicines Inc., a clinical-stage biotech company pioneering the advancement of best-in-class bispecific antibodies (bsAb) for inflammatory disorders and autoimmune diseases in areas of high unmet need, today announced successful completion of participant visits in the Phase 1b multiple-ascending dose study (MAD) of NAV-240.
Navigator Medicines Announces Positive Phase 1a Data from its Program of Potential Best-in-Class Bispecific Antibodies; NAV-240 Poised for Further Development in Inflammatory Disorders and Autoimmune DiseasesSCOTCH PLAINS, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Navigator Medicines Inc., a clinical-stage biotech company pioneering the advancement of best-in-class bispecific antibodies for inflammatory disorders and autoimmune diseases in areas of high unmet need, today announced further data from a Phase 1a double-blind, placebo-controlled, single ascending dose (SAD) study of its lead therapeutic candidate, NAV-240.
